Alcohol withdrawal syndrome (AWS) is a potentially life-threatening condition occurring within hours to days after cessation of or reduction in heavy, prolonged alcohol use, driven by CNS hyperexcitability from upregulated glutamate (NMDA) receptors and downregulated GABA activity. [2-3] Mortality is approximately 3% overall and up to 23% in hospitalized patients; delirium tremens carries a 5–10% mortality rate if untreated. [4-5]
1. History
- Time of last drink — the single most critical HPI element; symptoms begin 6–24 hours after cessation [6]
- Quantity, frequency, and duration of alcohol use (drinks/day, days/week, years of heavy use) [7]
- Prior withdrawal episodes — especially prior seizures or delirium tremens (strongest predictors of severe withdrawal) [8]
- Prior detox attempts and treatments used
- Concurrent substance use (benzodiazepines, opioids, stimulants) — polysubstance use is common and complicates management [7]
- Symptoms: tremor, sweating, nausea/vomiting, anxiety, insomnia, palpitations, headache
- Progression: are symptoms worsening, stable, or improving?
- Ability to tolerate oral intake and medications
2. Alarm Features
- Seizures (generalized tonic-clonic) — can occur as early as 2 hours, peak 24–48 hours; one-third of untreated seizure patients progress to delirium tremens [4][7]
- Delirium tremens — agitated delirium, visual hallucinations, severe autonomic instability (onset 72–96 hours, may last up to 7 days) [4][6]
- Hyperthermia (>38.3°C / 101°F)
- Severe tachycardia (HR >120), hypertension
- Refractory agitation despite adequate benzodiazepine dosing ("benzodiazepine-resistant withdrawal")
- Altered mental status disproportionate to expected withdrawal timeline
- Signs of Wernicke encephalopathy: ophthalmoplegia, ataxia, confusion [9]
- Concurrent GI bleeding, pancreatitis, or sepsis [4]
3. Medications
First-line — Benzodiazepines: [4][6][9]
- Long-acting (preferred for smoother withdrawal): diazepam 10 mg PO q6h taper or chlordiazepoxide 25–100 mg PO q6h taper
- Short-acting (preferred in liver disease): lorazepam 1–2 mg or oxazepam 15–30 mg [3][9]
- Symptom-triggered dosing preferred over fixed-schedule when monitoring is available [4][9]
- IV loading for moderate-severe: diazepam 5–10 mg q10–15 min or lorazepam 2–4 mg q10–15 min until adequate sedation [4]
Second-line / Adjuncts
- Phenobarbital — useful as adjunct or monotherapy; rapid onset, long half-life; use in monitored settings [4][6]
- Gabapentin — appropriate for mild withdrawal; also treats AUD long-term [5-6]
- Carbamazepine — alternative for mild-moderate withdrawal [6]
- Dexmedetomidine — ICU adjunct for refractory cases [9]
Contraindicated / Cautions
- Phenytoin — not effective for withdrawal seizures (should not be used unless treating a concomitant seizure disorder) [6]
- Beta-blockers — can lower seizure threshold; do not use to prevent/treat withdrawal seizures [6]
- Alpha-2 agonists (clonidine) — may help autonomic symptoms but do not prevent seizures or delirium [6]
- Avoid benzodiazepines with extensive hepatic metabolism (diazepam, chlordiazepoxide) in advanced liver disease [3][9]
Essential supplementation
- Thiamine — 100 mg IV/IM before glucose in hospitalized patients (prevent Wernicke encephalopathy); 100 mg PO daily × 3–5 days outpatient [4][9]
- Folate 1 mg daily, multivitamin
- Correct electrolytes: K⁺, Mg²⁺, phosphate [4]
4. Diet
- Maintain adequate hydration with noncaffeinated fluids (caffeine can worsen anxiety and tremor) [5]
- IV fluids (NS or LR) for patients unable to tolerate PO or with significant dehydration
- Nutritional support — patients are often malnourished; provide regular meals
- Avoid caffeine and energy drinks during acute withdrawal
- Long-term: balanced diet addressing chronic nutritional deficiencies (thiamine, folate, B12, zinc)
5. Review of Systems
- Neuro: tremor, seizures, headache, visual/auditory/tactile hallucinations, confusion, ataxia
- Psych: anxiety, agitation, insomnia, depression, suicidal ideation
- GI: nausea, vomiting, abdominal pain (pancreatitis?), GI bleeding (varices?)
- CV: palpitations, chest pain
- Constitutional: fever, diaphoresis
- Pulmonary: dyspnea, cough (aspiration risk)
6. Collateral History and Family History
- Collateral from family/friends is critical — patients frequently underreport alcohol intake [7]
- Confirm time of last drink, typical daily consumption, prior withdrawal complications
- Family history of alcohol use disorder (strong genetic component; heritability ~50%)
- Social context: housing stability, support system, ability to comply with outpatient follow-up [6]
- History of domestic violence, child safety concerns
7. Risk Factors
Risk factors for severe or complicated withdrawal: [5][7-8]
- History of prior withdrawal seizures or delirium tremens (strongest predictors)
- Multiple prior withdrawal episodes ("kindling" phenomenon)
- Heavy daily consumption and prolonged duration of use
- Age >65 years
- Concurrent medical illness (infections, trauma, hepatic dysfunction)
- Concurrent benzodiazepine or sedative-hypnotic dependence
- Elevated BAC on presentation (suggests high tolerance)
- Marked autonomic hyperactivity at presentation
- Elevated CIWA-Ar or PAWSS scores on initial assessment [4]
8. Differential Diagnosis
Must-not-miss diagnoses that mimic or coexist with AWS: [3][6]
- Hepatic encephalopathy — especially in patients with known cirrhosis
- CNS infection (meningitis/encephalitis) — fever + altered mental status
- Intracranial hemorrhage / traumatic brain injury — alcoholic patients are fall-prone
- Hypoglycemia — check point-of-care glucose immediately
- Thyrotoxicosis / thyroid storm — tremor, tachycardia, diaphoresis
- Sepsis — fever, tachycardia, altered sensorium
- Sedative-hypnotic withdrawal (benzodiazepines, barbiturates) — nearly identical presentation
- Anticholinergic toxicity — agitation, hallucinations, tachycardia (but dry skin, urinary retention)
- Sympathomimetic intoxication (cocaine, methamphetamine)
- Hyponatremia — seizures, confusion
- Drug poisoning [3]
- Wernicke encephalopathy — may coexist; classic triad of confusion, ataxia, ophthalmoplegia
Key distinguishing feature: AWS symptoms are relieved by administration of alcohol or benzodiazepines. [10]
9. Past Medical History
- Prior episodes of AWS, seizures, or delirium tremens
- Chronic liver disease / cirrhosis / alcoholic hepatitis
- Pancreatitis (acute or chronic)
- Cardiomyopathy (alcoholic)
- Peripheral neuropathy
- Psychiatric comorbidities: depression, anxiety, PTSD, bipolar disorder
- Prior head trauma / subdural hematoma
- Seizure disorder (independent of withdrawal)
- History of GI bleeding (varices, Mallory-Weiss)
10. Physical Exam
Vital signs — often the earliest objective indicators
- Tachycardiahypertensionhyperthermia[2][7]
Focused exam
- Tremor — coarse, postural; ask patient to extend arms with fingers spread
- Diaphoresis — palms, forehead, axillae
- Mental status — orientation to person/place/time/situation; ability to do serial additions
- Eyes — pupil size (mydriasis), nystagmus, extraocular movements (Wernicke)
- Skin — spider angiomata, palmar erythema, jaundice (chronic liver disease stigmata)
- Abdomen — hepatomegaly, splenomegaly, ascites, tenderness (pancreatitis)
- Neuro — gait (ataxia), deep tendon reflexes (hyperreflexia), asterixis (hepatic encephalopathy)
- Assess for trauma — head, face, extremities (falls are common)
11. Lab Studies
Recommended initial labs: [4][6-7]
- CBC — macrocytosis (MCV >100), thrombocytopenia
- CMP — glucose, electrolytes (hypokalemia, hypomagnesemia, hypophosphatemia), renal function
- Hepatic panel — AST, ALT (AST:ALT ratio >2:1 suggests alcoholic liver disease), bilirubin, albumin
- Magnesium and phosphate — frequently depleted; correct aggressively
- Blood alcohol concentration (BAC) — helps confirm recent use and gauge tolerance [6-7]
- Urine drug screen — rule out polysubstance use
- Lipase — if abdominal pain (pancreatitis)
- Coagulation studies (PT/INR) — if liver disease suspected
- Lactate — if sepsis concern
- Blood gas — if respiratory compromise
12. Imaging
- CT head without contrast — indicated if: new-onset seizures (to rule out structural pathology), focal neurological deficits, head trauma, altered mental status out of proportion to expected withdrawal [3]
- Chest X-ray — if fever, cough, or concern for aspiration pneumonia
- Imaging is not routinely necessary for uncomplicated, classic AWS presentations
- Abdominal imaging (CT or ultrasound) — if concern for pancreatitis, hepatic pathology, or GI bleeding source
13. Special Tests
Scoring systems — essential for guiding management
The CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, Revised) is the most widely used tool, scoring 10 domains (range 0–67): [2-4]
- <8: Mild — supportive care ± pharmacotherapy
- 8–15: Moderate — benzodiazepines recommended
- ≥19: Severe — aggressive pharmacotherapy, consider ICU [6]
The PAWSS (Prediction of Alcohol Withdrawal Severity Scale) is useful for predicting risk before withdrawal develops; score ≥4 suggests high risk. [4]
Point-of-care testing: bedside glucose, BAC
14. ECG
- Obtain ECG in patients with tachycardia, chest pain, palpitations, or electrolyte abnormalities
- Look for: sinus tachycardia (most common), atrial fibrillation ("holiday heart"), prolonged QTc (hypomagnesemia, hypokalemia), ST changes
- Arrhythmias are a recognized complication of severe AWS [7]
- Correct electrolytes (Mg²⁺, K⁺) before and during treatment
15. Assessment
AWS is a clinical diagnosis based on DSM-5 criteria: cessation/reduction of heavy alcohol use plus ≥2 withdrawal symptoms (autonomic hyperactivity, tremor, insomnia, nausea/vomiting, hallucinations, agitation, anxiety, seizures) causing significant distress, not attributable to another condition. [7][10]
Staging and timeline: [4-5]
Patients do not necessarily progress sequentially through stages; seizures can occur without preceding symptoms. [6] Symptoms generally peak at ~72 hours and markedly improve by days 5–7. [2]
16. Treatment Plan
Initial stabilization
- ABCs, IV access, continuous monitoring (telemetry if moderate-severe)
- Thiamine 100–500 mg IV/IM before glucose to prevent Wernicke encephalopathy [4][9]
- IV fluids (NS or LR) for hydration
- Correct electrolytes: Mg²⁺, K⁺, phosphate [4]
- Glucose if hypoglycemic
Pharmacotherapy by severity: [4][6]
Mild (CIWA-Ar <10): Supportive care ± gabapentin (300–600 mg TID) or carbamazepine (200 mg TID). Benzodiazepines optional. Thiamine 100 mg PO daily × 3–5 days. [5-6]
Moderate (CIWA-Ar 10–18): Benzodiazepines first-line. Symptom-triggered preferred:
- Chlordiazepoxide 25–50 mg PO q4–6h PRN, or
- Diazepam 5–10 mg PO q6–8h PRN
- Fixed taper alternative: diazepam 10 mg q6h day 1 → q8h day 2 → q12h day 3 → qHS day 4 [4]
Severe (CIWA-Ar ≥19): Aggressive IV treatment: [4][6]
- Diazepam 5–10 mg IV q10–15 min, or lorazepam 2–4 mg IV q10–15 min until adequate sedation
- Phenobarbital 130–260 mg IV as adjunct or alternative
- ICU admission for refractory cases; consider midazolam drip or dexmedetomidine [9]
Seizure management: [6]
- Lorazepam 2–4 mg IV or diazepam 5–10 mg IV immediately
- Parenteral route preferred (IV > IM)
- Phenytoin is not effective for withdrawal seizures
- Monitor for recurrence and progression to delirium tremens
17. Disposition
Discharge criteria (from ED to outpatient): [6]
- CIWA-Ar <10 and improving
- No history of complicated withdrawal (seizures, DTs)
- No significant medical/psychiatric comorbidities
- Not currently intoxicated
- Able to tolerate oral medications
- Reliable support system and safe home environment
- Able to follow up within 24–48 hours
Admission criteria: [8][11]
- CIWA-Ar ≥20 or severe/complicated symptoms
- History of delirium tremens or withdrawal seizures
- Active seizure during current episode
- Inability to tolerate oral medications
- Significant comorbidities (GI bleeding, pancreatitis, liver failure, sepsis)
- Concurrent sedative-hypnotic withdrawal
- Active psychosis, severe cognitive impairment, or suicidal ideation
- Failed outpatient withdrawal management
- Homelessness or no safe environment
ICU admission: Delirium tremens, refractory symptoms despite adequate benzodiazepine dosing, hemodynamic instability, respiratory compromise, status epilepticus [4]
18. Follow Up / Return Precautions
Follow-up timing
- Outpatient patients: daily or every-other-day reassessment for the first 3–5 days [5]
- Repeat CIWA-Ar at each visit
- Transition to AUD treatment (naltrexone, acamprosate, or gabapentin) once withdrawal resolves [9]
Return-to-ED precautions — instruct patients and caregivers to return immediately for:
- New or recurrent seizures
- Confusion, disorientation, or hallucinations
- Fever >101°F
- Inability to keep down fluids or medications
- Worsening tremor or agitation despite medications
- Chest pain, severe abdominal pain
- Suicidal thoughts
Patient counseling
- Withdrawal symptoms typically peak at 48–72 hours and improve significantly by day 5–7 [2]
- Maintain low-stimulation environment, avoid caffeine [5]
- Do not drive while on benzodiazepines
- Emphasize that detox is not treatment — connect with addiction medicine, counseling, and support groups for long-term recovery [12]
References
1. Management of Alcohol Withdrawal Syndrome in Patients With Alcoholic Liver Disease. — Chand PK, Panda U, Mahadevan J, Murthy P. Journal of Clinical and Experimental Hepatology. 2022.
2. Recognition and Management of Withdrawal Delirium (Delirium Tremens). — Schuckit MA. The New England Journal of Medicine. 2014.
3. Management of Alcohol Use Disorder: A Gastroenterology and Hepatology-Focused Perspective. — Díaz LA, König D, Weber S, et al. The Lancet. Gastroenterology & Hepatology. 2025.
4. Managing Selected Chronic Conditions in Hospitalized Patients. — Gauer RL, Abellada A, Stewart M, Kozloski R. American Family Physician. 2024.
5. Alcohol Withdrawal Syndrome: Outpatient Management. — Tiglao SM, Meisenheimer ES, Oh RC. American Family Physician. 2021.
6. Clinical Practice Guideline on Alcohol Withdrawal Management. — Anika Alvanzo MD MS DFASAM FACP, Kurt Kleinschmidt MD FASAM, Julie A. Kmiec DO FASAM, et al American Society of Addiction Medicine (2020). 2020.
7. Will This Hospitalized Patient Develop Severe Alcohol Withdrawal Syndrome?The Rational Clinical Examination Systematic Review. — Wood E, Albarqouni L, Tkachuk S, et al. The Journal of the American Medical Association. 2018.
8. Management of Substance Use Disorder (SUD) (2021). — Timothy Atkinson PharmD, Charolotte Baldridge FNP, Jennifer Burden PhD MS, et al Department of Veterans Affairs. 2021.
9. Identification and Treatment of Alcohol Use Disorder. — Haber PS. The New England Journal of Medicine. 2025.
10. Diagnostic and Statistical Manual of Mental Disorders. — Dilip V. Jeste, Jeffrey A. Lieberman, David Fassler, et al American Psychiatric Association (2022). 2022.
11. Management of Substance Use Disorders: Guidelines From the VA/DoD. — Ford B, Smith E, Richards A. American Family Physician. 2022.
12. Alcohol Use Disorder: From Risk to Diagnosis to Recovery. — George F. Koob PhD, Rachel I. Anderson PhD, Raye Z. Litten PhD, Laura E. Kwako PhD, Maureen B. Gardner National Institute on Alcohol Abuse and Alcoholism (2025). 2025.